Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1563, 2006-01, pp. : 16-16
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Docetaxel added to standard chemotherapy does not compromise QOL
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 515, 2006-01 ,pp. :
Access to resources
Recommend
Doxorubicin + docetaxel vs standard chemo in breast cancer
Inpharma, Vol. 1, Iss. 1512, 2005-01 ,pp. :
Sorafenib therapy does not compromise the QOL of patients with renal cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 516, 2006-01 ,pp. :
Exemestane: clinical benefits without QOL compromise
Inpharma, Vol. 1, Iss. 1530, 2006-01 ,pp. :
Exemestane: clinical benefits without QOL compromise
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 499, 2006-01 ,pp. :